PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) RETAIN PHOSPHORUS AND CAN DEVELOP HYPERPHOSPHATEMIA. HIGH SERUM PHOSPHORUS CAN PRECIPITATE SERUM CALCIUM RESULTING IN ECTOPIC CALCIFICATION. WHEN THE PRODUCT OF SERUM CALCIUM AND PHOSPHORUS CONCENTRATIONS (CA Γ P) EXCEEDS 55 MG 2 /DL 2 , THERE IS AN INCREASED RISK THAT ECTOPIC CALCIFICATION WILL OCCUR. HYPERPHOSPHATEMIA PLAYS A ROLE IN THE DEVELOPMENT OF SECONDARY HYPERPARATHYROIDISM IN RENAL INSUFFICIENCY. AN INCREASE IN PARATHYROID HORMONE (PTH) LEVELS IS CHARACTERISTIC OF PATIENTS WITH CHRONIC RENAL FAILURE. INCREASED LEVELS OF PTH CAN LEAD TO OSTEITIS FIBROSA, A BONE DISEASE. A DECREASE IN SERUM PHOSPHORUS MAY DECREASE SERUM PTH LEVELS.
TREATMENT OF HYPERPHOSPHATEMIA INCLUDES REDUCTION IN DIETARY INTAKE OF PHOSPHATE, INHIBITION OF INTESTINAL PHOSPHATE ABSORPTION WITH PHOSPHATE BINDERS, AND REMOVAL OF PHOSPHATE WITH DIALYSIS. RENAGEL TAKEN WITH MEALS HAS BEEN SHOWN TO DECREASE SERUM PHOSPHORUS CONCENTRATIONS IN PATIENTS WITH ESRD WHO ARE ON HEMODIALYSIS. RENAGEL DOES NOT CONTAIN ALUMINUM OR OTHER METALS AND DOES NOT CAUSE ALUMINUMIN INTOXICATION.
RENAGEL TREATMENT ALSO RESULTS IN A LOWERING OF LOW-DENSITY LIPOPROTEIN (LDL) AND TOTAL SERUM CHOLESTEROL LEVELS.